INDEPENDENT Age: 60 Director Since: 2020 Committees: Audit Committee (Chair) Ms. Rhoads most recently served as Chief Financial Officer of Forty Seven, Inc., a formerly publicly-traded biotechnology company, from March 2018 to June 2020. Previously, Ms. Rhoads was the Executive Vice President and Chief Financial Officer of Zogenix, Inc., a formerly publicly-traded pharmaceutical company, from 2010 to January 2017. From 2000 to the end of 2009, Ms. Rhoads served as the Chief Financial Officer of Premier, Inc., a healthcare supply management company. From 1998 to 2000, she was the Vice President, Strategic Initiatives at Premier, Inc., and from 1993 to 1998, she was an investment professional with The Sprout Group, an institutional venture capital firm. Ms. Rhoads holds a B.S. in Finance from the University of Arkansas and an M.B.A. from Harvard Business School. Ms. Rhoads has a strong financial background as a former Chief Financial Officer of Forty Seven, Inc., Zogenix, Inc. and Premier, Inc. Ms. Rhoads is an audit committee financial expert as a result of her prior experience as Chief Financial Officer and as a board member and chair of the audit committee of other U.S. public companies. She also has extensive executive leadership and governance experience through her service on the boards of directors of other companies. Other Current Public Company Directorships: Globus Medical Inc. Audit Committee (chair) and Nominating and Corporate Governance Committee Prior Public Company Directorships Within the Past 5 Years: iTeos Therapeutics until August 2025 Audit Committee (chair), Compensation Committee and Nominating and Corporate Governance Committee Repare Therapeutics until January 2026 Audit Committee (chair) and Nominating and Corporate Governance Committee